PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known Application Number **New Application** INFORMATION DISCLOSURE Filing Date herewith STATEMENT BY APPLICANT Dewdney, Nolan James et al. First Named Inventor unassigned Art Unit (use as many sheets as necessary) Examiner Name unassigned of 1 **R0164B-REG** Sheet Attorney Docket Number

011001					
			J.S. PATENT DO	CUMENTS	
Examiner Initials *	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)		Document	
	A1	US-2002/0061879 A1	05-23-2002	David S. Garvey, et al.	
	A2	US-3,594,480	07-20-1971	Timothy H. Cronin, et al.	
	А3	US-4,672,116	06-09-1987	Victor T. Bandurco, et al.	
	A4	US-5,084,463	01-28-1992	John A. Butera, et al.	
	A5	US-6,313,294 B1	11-06-2001	Wen-Chih Chou, et al.	

		FOREIC	ON PATENT DOCU	IMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁸
	B1	WO 92/01675 A1 (PCT)	02-06-1992	Rhone-Poulenc Rorer S.A. (FR)		
	B2	WO 98/38984 A2 (PCT)	09-11-1998	Sugen, Inc. (U.S.)		
	В3	WO 01/32632 A2 (PCT)	05-10-2001	Eli Lilly and Company (U.S.)		
	B4	WO 01/38315 A1 (PCT)	05-31- 2001	Warner-Lambert Company (U.S.)		
	B5	WO 01/64646 A2 (PCT)	09-07-2001	Tularik Inc (U.S.). & Sumitomo Pharma- ceuticals Co., Ltd. (JP)		
	В6	WO 02/085908 A1 (PCT)	10-31-2002	Purdue Research Foundation (U.S.) and Endocyte, Inc. (U.S.)		
	B7	WO 02/50045 A1 (PCT)	06-27-2002	Biota Scientific Management Pty (AU)		
	B8	WO 02/08224 A1 (PCT)	01-31-2002	SmithKline Beecham PLC (GB)		
	В9	EP 1 110 552 A1	06-27-2001	Aventis Pharma S.A. (FR)		

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Doc. #124158 Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.